The FDA is receiving more reports about a rare white blood cell cancer (known as Hepatosplenic T-Cell Lymphoma or HSTCL). Most of the reports of this cancer have been found in adolescents and young adults being treated for Crohn’s disease and ulcerative colitis with medicines known as tumor necrosis factors (TNF) blockers, as well as with azathioprine, and/or mercaptopurine. TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab).
The FDA has now received 43 reports of patients with this white blood cell cancer from people taking bowel drugs, including Remicade.
Certainly, the FDA is not calling for a recall of these drugs. What it is saying is: “everyone should keep their heads up.” You can read exactly what the FDA is saying here.